Company news

Organon & Co. news in 2026

Organon & Co.'s news releases, calls and decks from 2026, newest first.

View company

New Real-World Evidence Presented by Organon at the American College of Rheumatology (ACR) Annual Meeting Evaluated a Large-Scale Switch to HADLIMA® (adalimumab-bwwd) Across United States Veterans Affairs Healthcare System

November 7, 2026

Organon to Present New Analysis on VTAMA® (tapinarof) cream, 1% at the 2026 American College of Allergy, Asthma & Immunology Annual Scientific Meeting

November 5, 2026

Organon Announces Quarterly Dividend

October 30, 2026

Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing

October 19, 2026

Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA®, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting

October 16, 2026

Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference

October 1, 2026

Organon Canada announces the Approval and Availability of NDUVRA® (tapinarof cream), 1%, a New Steroid-Free Topical Treatment for Moderate to Severe Atopic Dermatitis in Adult and Pediatric Patients 2 Years of Age and Older

September 28, 2026

Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine Device

September 14, 2026

Organon Opens REMS Program for MIUDELLA® Ahead of Anticipated Commercial Availability

August 11, 2026

Organon Announces Quarterly Dividend

July 31, 2026

New Analysis of Phase 3 Pooled Data for Organon’s VTAMA® (tapinarof) cream, 1%, Demonstrates Early, Consistent Improvements in Atopic Dermatitis Patients Across Pediatric Age Groups and in Adults1

July 24, 2026

Organon to Report Second Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing

July 16, 2026

Organon to Present New Analysis on VTAMA® (tapinarof) cream, 1%, at the 2026 Society for Pediatric Dermatology Annual Meeting

July 7, 2026

Organon Canada and Henlius Expand Access to Denosumab Treatments With Launch of BILDYOS® (denosumab injection) and TUZEMTY® (denosumab injection), Biosimilars to PROLIA and XGEVA

June 23, 2026

Organon Completes Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device

June 22, 2026

Organon and Samsung Bioepis Expand Agreement to Commercialize PYZCHIVA® (ustekinumab), a Biosimilar Referencing STELARA® (ustekinumab) in Canada

June 18, 2026

Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19

June 10, 2026

Organon to Present New Research on Access and Value at ISPOR 2026

May 15, 2026

Organon Reports Results for the First Quarter Ended March 31, 2026

April 30, 2026

Organon Cancels First Quarter Earnings Call

April 29, 2026

European Commission (EC) Approves Henlius and Organon's POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe

April 29, 2026

European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe

April 29, 2026

Sun Pharma signs Definitive Agreement to Acquire Organon

April 26, 2026

Organon To Report First Quarter 2026 Results and Host Conference Call on May 7, 2026

April 16, 2026

Organon’s VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the 2026 American Academy of Dermatology Guidelines for Pediatric Atopic Dermatitis

April 15, 2026

Organon accelerates Women's Health progress across Asia Pacific with 2026 Her Health Grants

March 29, 2026

Organon Debuts New Analysis of VTAMA® (tapinarof) cream, 1%, Phase 3 Pooled Data Demonstrating Early and Consistent Skin Clearance and Itch Improvement in Atopic Dermatitis Patients Down to 2 Years of Age

March 27, 2026

New Analysis of Organon’s VTAMA® (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down to 2 Years of Age with Atopic Dermatitis

February 27, 2026

Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device

February 23, 2026

Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025

February 12, 2026

Organon Launches Third Edition of Women's Health Accelerator Program Across Middle East, Turkey & Africa

February 4, 2026

Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026

January 29, 2026

Organon Completes Divestiture of JADA® System to Laborie

January 28, 2026

Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON(R) (etonogestrel implant) 68 mg Radiopaque

January 19, 2026

Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque

January 16, 2026

Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway

January 8, 2026

Calls in 2026

Decks in 2026